Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma

被引：10

作者：

Mahar, Patrick D. ^{[1
,2
]}

Zubrinich, Celia M. ^{[3
]}

Manuelpillai, Nick ^{[1
]}

Foley, Peter ^{[4
]}

机构：

[1] Skin Hlth Inst Inc, Melbourne, Vic, Australia

[2] Royal Childrens Hosp, Melbourne, Vic, Australia

[3] Alfred Hlth, Melbourne, Vic, Australia

[4] St Vincents Hosp, Melbourne, Vic, Australia

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷 / 04期

关键词：

biologics; psoriasis; psoriatic arthritis; asthma; nasal polyps; RHEUMATOID-ARTHRITIS; THERAPY;

D O I：

10.1111/ajd.13676

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Biological disease-modifying agents have increasingly become available for the effective treatment of both cutaneous and non-cutaneous inflammatory conditions. We report a case of a woman treated successfully for psoriasis and psoriatic arthritis with the IL-17 inhibitor secukinumab whilst simultaneously being treated for severe asthma and nasal polyps, initially with the IL-5 inhibitor benralizumab, followed by dupilumab, a monoclonal antibody that targets the IL-4 receptor alpha subunit which blocks signalling from both IL-4 and IL-13.

引用

页码：506 / 508

页数：3

共 50 条

[21] Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update
Walsh, Garry M.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (10) : 1237 - 1243
[22] Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
Rodriguez-Fernandez, Karine
Mangas-Sanjuan, Victor
Merino-Sanjuan, Matilde
Martorell-Calatayud, Antonio
Mateu-Puchades, Almudena
Climente-Marti, Monica
Gras-Colomer, Elena
PHARMACEUTICS, 2022, 14 (03)
[23] Secukinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients aged six years and older
Krajewski, Piotr K.
Szepietowski, Jacek C.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (07) : 711 - 716
[24] Use of dupilumab on the treatment of moderate-to-severe asthma: a systematic review
Bassani, Cintia
Rossi, Larissa
Siveri, Kaian
Sferelli, Rafaella Lorenzon
Saraiva, Leonardo
Tanno, Luciana Kase
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (09): : 1223 - 1228
[25] Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
Rathinam, Kiran Kumar
Abraham, Justin Jacob
Vijayakumar, Thangavel Mahalingam
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2019, 91 : 45 - 51
[26] Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma
Gawlewicz-Mroczka, Agnieszka
Przybyszowski, Marek
Bochenek, Grazyna
Mroczka, Maria
Sladek, Krzysztof
RESPIRATORY MEDICINE CASE REPORTS, 2024, 52
[27] Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Zhang, Jinsui
Xia, Zemin
Guo, Wanjie
Ren, Xiaoxiao
Liu, Fang
Ratnaparkhi, Gargi
Pagada, Amit
Subramanian, Subhashini
Hu, Min
Chen, Wen
DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2681 - 2696
[28] Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis
Di Tullio, Francesca
Odorici, Giulia
Lasagni, Claudia
Capobianco, Marco
Conti, Andrea
Mandel, Victor Desmond
DERMATOLOGIC THERAPY, 2020, 33 (06)
[29] BRODALUMAB Anti-IL-17 Receptor Human Monoclonal Antibody Treatment of Psoriasis Treatment of Asthma
Gajdosik, Z.
DRUGS OF THE FUTURE, 2012, 37 (12) : 837 - 840
[30] Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype
Al Efraij, Khalid
FitzGerald, J. Mark
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (07) : 669 - 676

← 1 2 3 4 5 →